Biochemical markers of neurotoxicity. A review of mechanistic studies and applications

Human and Experimental Toxicology

Volumn 15, Issue SUPPL. 1, 1996, Pages

  Manzo, Luigi ^a   Artigas, Francesc ^b   Martínez, Emili ^b   Mutti, Antonio ^c   Bergamaschi, Enrico ^c   Nicotera, Pierluigi ^a,d   Tonini, Marcello ^a   Candura, Stefano M ^a   Ray, David E ^e   Costa, Lucio G ^a,f  

^a UNIVERSITY OF PAVIA   (Italy)

^b CSIC   (Spain)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITY OF KONSTANZ   (Germany)

^e UNIVERSITY OF LEICESTER   (United Kingdom)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Biological markers; D fenfluramine; Lead; Manganese; Serotonin; Styrene

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BIOCHEMICAL MARKER; CALCIUM ION; DEXFENFLURAMINE; DISULFOTON; DOPAMINE BETA MONOOXYGENASE; KAINIC ACID; LEAD; MANGANESE; MERCURY; METAL; MUSCARINIC RECEPTOR; MYELIN BASIC PROTEIN; PESTICIDE; POLYAMINE; PROLACTIN; STYRENE; TRIETHYLTIN;

ARTICLE; BLOOD CELL; BLOOD LEVEL; BODY FLUID; HUMAN; NERVOUS TISSUE; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; OCCUPATIONAL EXPOSURE; PERIPHERAL LYMPHOCYTE; PHARMACOLOGY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PSYCHOBIOLOGY; SECOND MESSENGER;

ANIMALS; BIOLOGICAL MARKERS; ENVIRONMENTAL MONITORING; HUMANS; NERVOUS SYSTEM DISEASES; SYNAPTIC TRANSMISSION;

ANIMALIA; GYMNOMYZA SAMOENSIS;

EID: 15844406929     PISSN: 01445952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (118)

1. Costa LG, Manzo L. Biochemical markers of neurotoxicity; research strategies and epidemiological applications. Toxicol Lett 1995; 77: 137-144.
2. Fowle JR, Sexton K. EPA priorities for biologic markers research in enviromental health. Environ Health Persp 1992; 98: 235-241.
3. Manzo L, et al. Mechanisms of neurotoxocity; applications to human bio-monitoring. Toxicology Letters 1995; 77: 63-72.
4. Reuhl KR. Delayed expression of neurotoxicity: the problem of silent damage. Neurotoxicology 1991; 12: 341-346.
5. Henderson RF, Bechtold WE, Bond JA, Sun JD. The use of biological markers in toxicology. CRC Crit Rev Toxicol 1989; 20; 65-82.
6. Romberg L. Use of biomarkers in quantitative risk assessment. In: Use of Biomarkers in Assessing Health and Enviromental Impact of Chemical Pollutants. Travis CC (ed) pp. 31-46. New York: Plenum Press, 1993.
7. Bergmark E, Calleman CJ, He F, Costa LG. Determination of hemoglobin adducts in humans occupationally exposed to acrylamide. Toxicol Appl Pharmacol 1993; 120: 45-54.
8. Bergmark E, Calleman CJ, Costa LG. Formation of hemoglobin adducts of acrylamide and its epoxide metabolite glycidamide in the rat. Toxicol Appl Pharmacol 1991; 111: 352-363.
9. Silbergeld EK, Davis DL. Role of biomarkers in identifying and understanding enviromentally induced disease. Clin Chem 1994; 40: 1363-1367.
10. Tilson HA, MacPhail RC, Crofton KM. Defining neurotoxicity in a decision-making context. Neurotoxicology 1995; 16: 363-376.
11. Anger WK. Behavioural biomarkers to identify neurotoxic effects. In: Use of Biomarkers in Assessing Health and Environmental Impacts of Chemical Pollutants. Travis CC [ed) pp. 183-200. New York: Plenum Press, 1993.
12. 2 dopamine receptor binding characteristics in vivo in patients with alcohol dependence. Psychopharmacology 1994; 116: 285-290.
13. Triebig G, Lang C. Brain imaging techniques applied to chronically solvent-exposed workers: current results and clinical evaluation. Environ Res 1993; 61: 239-250.
14. Silbergeld EK. Neurochemical approaches to developing biochemical markers of neurotoxicity: review of current status and evaluation of future prospects. Environ Res 1993; 63: 274-286.
15. Costa LG. Peripheral models for the study of neurotransmitter receptors: their potential application to occupational health. In: Occupational and Environmental Chemical Hazards, Foà V, Emmett EA, Maroni M, Colombi A. (eds) pp. 524-528. Chichester: Ellis Horwood, 1987.
16. Costa LG. Effects of neurotoxicants on brain neurochemistry. In: Neurotoxicology, Tilson HA, Mitchell CL. (eds) pp. 101-123. New York: Raven Press, 1992.
17. Costa LG. Cell signaling and neurotoxic events. In: Principles of Neurotoxicology, Chang LW (ed) pp 475-493. New York: Marcel Dekker, 1994.
18. Castoldi A, et al. Biomarkers in environmental medicine: alterations of cell signalling as early indicators of neurotoxicity. Funct Neurol 1994; 9, 101-109.
19. Lotti M. Organophosphate-induced delayed polyneuropathy in humans: perspectives for biomonitoring. Trends Pharmacol Sci 1987; 8, 175-176.
20. Silbergeld EK. New approaches to monitoring environmental neurotoxins. Ann NY Acad Sci 1993; 694: 62-71.
21. Costa LG, Kaylor G, Murphy SD. Muscarinic cholinergic binding sites on rat lymphocytes. Immunopharmacology 1988; 16, 139-149.
22. Costa LG, Kaylor G, Murphy SD. In vitro and in vivo modulation of cholinergic muscarinic receptors in rat lymphocytes and brain by cholinergic agents. Int J Immunopharmacol 1990; 12, 67-75.
23. Fitzgerald BB, Costa LG. Modulation of muscarinic receptors and acetylcholinesterase activity in lymphocytes and in brain areas folowing repeated organophosphate exposure in rats. Fundam Appl Toxicol 1993; 20: 210-216.
24. 2 receptors, in rat and human lymphocytes. Immunopharmacology 1991; 22: 93-106.
25. Su TP. Sigma receptors. Putative links between nervous, endocrine and immune systems. Eur J Biochem 1991; 200: 633-642.
26. Vilner BJ, de Costa BR, Bowen WD. Cytotoxic effects of sigma ligands; sigma receptor-mediated alterations in cellular morphology and viability. J Neurosci 1995; 15: 117-134.
27. Monnet FP. Implication des récepteurs sigma dans les syndroms schizophréniques. Approche physiopathologique. Presse Méd 1993; 22: 218-223.
28. Lesch KP, Wolozin BL, Murphy DL, Riederer P. Primary structure of the human platelet serotonin uptake site - identity with the brain serotonin transporter. J Neurochem 1993; 60: 2319-2322.
29. Beving H et al. Effect on the uptake kinetics of serotonin (5-hydroxytryptamine) in platelets from workers with long-term exposure to organic solvents: a pilot study. Scand J Work Environ Health 1984; 10: 229-234.
30. Lam HR, Tarding F, Stockholm J, Gyatelberg F. Human platelet 5-hydroxytryptamine concentration as a tool in the prediction of solvent induced neurotoxic effects. Acta Pharmacol Toxicol 1985; 56, 233-238.
31. Checkoway H et al. Peripheral markers of neurochemical function among styrene-exposed workers. Br J Ind Med 1992; 49: 560-565.
32. Martin F, Artigas F. Simultaneous effects of p-chloroamphetamine, d-fenfluramine, and reserpine on free and stored 5-hydroxytryptamine in brain and blood. J Neurochem 1992; 59: 1138-1144.
33. Celada P, Martin F, Artigas F. Effect of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue. Life Sci 1994; 55; 1237-1243.
34. Cohn J, Cory-Slechta DA. Assessment of the role of dopamine systems in lead-induced learning impairments using a multiple schedule of repeated acquistion and performance. Neurotoxicology 1994; 15: 913-926.
35. Subhash MN, Padmashree TS. Effect of manganese on biogenic amine metabolism in regions of the rat brain. Food Chem Toxicol 1991; 29: 579-582.
36. Husain R, Srivastava SP, Mushtag M, Seth PK. Effect of styrene on levels of serotonin, noradrenaline, dopamine and activity of acetylcholinesterase and monoamine oxadise in rat brain. Toxicol Lett 1980; 7: 47-50.
37. Mutti A. Mechanisms and biomarkers of solvent-induced behavioural and neuroendocrine effects. In: Use of Biomarkers in Assessing Health and Environmental Impact of Chemicals. Travis CC (ed) pp. 183-199. New York: Plenum Press, 1993.
38. Chen K, Wu HF, Shih JC. The deduced amino acid sequences of human platelet and frontal cortex monoamine oxadise B are identical. J Neurochem 1993; 61: 187-190.
39. Checkoway et al. Platelet monoamine oxidase B activity in workers exposed to styrene. Int Arch Occup Environ Health 1995; 66: 359-362.
40. Lee MK, Nohta H, Ohkura Y. Assay for dopamine β-hydroxylase in human plasma and rat serum by high-performance liquid chromatography with fluorimetric detection. J Chromatogr 1987; 42: 237-244.
41. Smargiassi A et al. Peripheral markers of catecholamine metabolism among workers occupationally exposed to manganese (Mn). Toxicol Lett 1995; 77: 329-333.
42. Shukla GS, Changra SV. Striatal dopamine turnover and L-dopa treatment after short-term exposure to manganese. Arch Toxicol 1981; 47: 191-196.
43. Healy D, Carney PA, O'Halloran, A, Leonard NE. Peripheral adrenoceptors and serotonin receptors in depression: changes associated with response to treatment with trazodone or amitriptyline. J Affect Disord 1985; 9: 286-296.
44. Mazzola P et al. Early decrease in density of mononuclear leukocyte beta-adrenoceptors in depressed patients following amineptine treatment: possible relation to clinical efficiency. Progr Neuro-Psychopharmacol Biol Psychiat 1991; 15: 357-367.
45. Thies-Flechtner K, Weigel I, Muller-Oerling-hausen B. 5-HT uptake in platelets of lithium-treated patients with affective disorders and of health controls. Pharmacopsychiat 1994; 27 (suppl): 4-6.
46. Dubovsky SL, Thomas M, Hijazi A, Murphy J. Intracellular calcium signalling in peripheral cells of patients with bipolar affective disorders. Eur Arch Psychiat Clin Neurosci 1994; 243: 229-234.
47. 2+ response in neutrophils from patients under chronic lithium therapy. Eur Arch Psychiat Clin Neurosci 1994; 243: 240-243.
48. Whiteford HA et al. Mianserin-indiced up-regulation of serotonin receptors on normal human platelets in vivo. Life Sciences 1993; 53: 371-376.
49. Watanaba H et al. Platelet cyclic GMP. A potentially useful indicator to evaluate the effects of nitroglycerin and nitrate tolerance. Circulation 1993; 88: 29-36.
50. Raine AEG et al. Hyperparathyroidism, platelet intracellular free calcium and hypertension in chronic renal failure. Kidney Int 1993; 43: 700-705.
51. Muller R et al. Changes in plasma norepinephrine concentration and thrombocyte alpha-2 adrenoceptor density during long-term antihypertansive therapy with nitrendipine and captopril. J Cardiov Pharmacol 1994; 24: 429-433.
52. 3 or calcium channels blocker. Am J Nephrol 1993; 13: 467-472.
53. De Petrillo PB, Abernethy DR, Wainer IW, Andrawis NS. Verapamil decreases lymphocyte protein kinase C activity in humans. Clin Pharmacol Ther 1994; 55: 44-49.
54. Glue P et al. Effects of chronic adrenoceptor blockade on platelet and lymphocyte α2-adrenoceptor binding in human volunteers. Life Sci 1991; 49: PL21-25.
55. Wirtz-Justice A. Platelet research in psychiatry. Experientia 1988; 44: 145-151.
56. Pandey SC, Kin SW, Davis JM, Pandey GN. Platelet serotonin-2 receptors in obsessive-compulsive disorder. Biol Psychiat 1993; 33: 367-372.
57. Werstiuk ES, Steiner M, Burns T. Studies on leukocyte beta-adrenergic receptors in depression: a critical appraisal. Life Sci 1990; 47, 85-105.
58. Sherf F, Hallman J, Oreland L. Low platelet gamma-aminobutyrate aminotransferase and monoamino oxidase activities in chronic alcoholic patients. Alcohol Clin Exp Res 1992; 16: 1014-1020.
59. Rommelspacher H, May T, Dufeu P, Schmidt LG. Longitudinal observations of monoamine oxidase B on alcoholics: differentiation of marker characteristics. Alcohol Clin Exp Res 1994; 18: 1322-1329.
60. Faraj BA et al. Platelet monoamine oxidase activity in alcoholics, alcoholics with drug dependence and cocaine addicts. Alcohol Clin Exp Res 1994; 18: 1114-1120.
61. Rossi et al. Modification of cell signalling in the cytotoxicity of metals. Pharmacol Toxicol 1991; 68: 424-426.
62. Nicotera P, Bellomo G, Orrenius S. Calcium-mediated mechanisms in chemically induced cell death. Ann Rev Pharmacol Toxicol 1992; 32: 449-470.
63. Markovac J, Goldstein GW. Picomolar concentrations of lead stimulate brain protein kinase C. Nature 1988; 334: 711-773.
64. 2 signalling by inorganic mercury in PC12 cells. FASEB J 1993; 7: 1507-1514.
65. Brandt-Rauf PW, DeVivo I, Marion MJ, Hemminki K. The molecular epidemiology of growth signal transduction proteins. JOEM 1995; 37: 77-83.
66. Putney JW. Excitement about calcium signalling in inexcitable cells. Science 1993; 262: 670-678.
67. Sargeant P, Sage SO. Calcium signalling in platelets and other nonexcitable cells. Pharmacol Ther 1994; 64: 395-443.
68. Scharff O, Foder B. Regulation of cytosolic calcium in blood cells. Phys Rev 1993; 73: 547-582.
69. Heemskerk JWM, Sage SO. Calcium signalling in platelets and other cells. Platelets 1994; 5: 295-316.
70. June CH et al. Potential clinical applications of signal transduction measurements in marrow transplantation and HIV-1 infection. Ann NY Acad Sci 1993; 677: 225-232.
71. Zemel MB et al. Altered platelet calcium metabolism as an early predictor of increased peripheral vascular resistance and pre-eclampsia in urban black women. N Engl J Med 1990; 323: 478-480.
72. 2+ in mononuclear blood cells from demented patients and healthy control. Eur Arch Psychiat Clin Neurosci 1994; 243: 224-228.
73. Eckert A et al. Platelet and lymphocyte free intracellular calcium in affective disorders. Eur Arch Psychiat Clin Neurosci 1994; 243: 235-239.
74. 2+ in single T-lymphocytes from depressed patients and healthy controls. Eur Arch Psychiat Clin Neurosci 1994; 243: 214-217.
75. Hudson CJ, Young LT, Li PP, Warsh JJ. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia. Synapse 1993; 13: 278-293.
76. Mattson MP, Rydel RE, Liedenburg I, Smithswintosky VL. Altered calcium signal and neuronal injury. Stroke and Alzheimer's disease as examples. In: Markers oif Neuronal Injury and Degeneration, Johnnessen JN. (ed) pp. 1 -21. New York: New York Academy of Sciences, 1993.
77. Tabakoff B et al. Differences in platelet enzyme activity between alcoholics and nonalcoholics. N Engl J Med 1988; 318: 134-139.
78. Diamond I, Wrubel B, Estrin W, Gordon A. Basal and adenosine receptor-stimulated levels of cAMP are reduced in lymphocytes from alcoholic patients. Proc Natl Acad Sci USA 1987; 84: 1413-1417.
79. Simonsson P, Ailing C. The 5-hydroxytryptamine stimulated formation of inositol monophosphate is inhibited in platelets from alcoholics. Life Sci 1988; 42: 385-391.
80. Tan XX et al. Effects of inorganic and organic mercury on intracellular calcium levels in rat T lymphocytes. J Toxicol Environ Health 1993; 38: 159-170.
81. Duman RS, Heninger GR, Nestler EJ. Molecular psychiatry. Adaptations of receptor-coupled signal transduction pathways underlying stress-and drug-induced neural plasticity. J Nerv Ment Dis 1994; 182: 692-700.
82. Risby ED et al. The mechanism of action of lithium. Arch Gen Psychiatry 1991; 48: 513-524.
83. Ader R, Cohen N, Felten D. Psychoneuroimmunology: interactions between the nervous system and the immune system. Lancet 1995; 345: 99-103.
84. Kavanagh TJ et al. The effect of 1-chloro-2, 4-dinitrobenzene exposure on antigen receptor (CD3)-stimulated transmembrane signal transduction in purified subsets of human peripheral blood lymphocytes. Toxicol Appl Pharmacol 1993; 119: 91-99.
85. Koller LD. Biomarkers of immunotoxicology. In: Use of Biomarkers in Assessing Health and Environmental Impacts of Chemical Pollutants. Travis CC (ed) pp. 201-207, New York: Plenum Press, 1993.
86. Brambilla F. Drug-induced neuroendocrine disorders: neuroleptics and hormones. In: Neurotoxicology. Blum K, Manzo L. (eds) pp. 83-89. New York: Marcel Dekker, 1985.
87. Yatham L, Steiner M. Neuroendocrine probes of serotonergic function: a critical review. Life Sci 1993; 53: 447-463.
88. Mutti A et al. Serum prolactin in subjects occupationally exposed to manganese. Ann Clin Lab Sci in press.
89. Johnstone EC, Ferrier IN. Neuroendocrine markers of CNS drug effects. Br J Clin Pharmacol 1980; 10: 5-21.
90. O'Callaghan JP. Assessment of neurotoxicity using assays on neuron- and glia-localized proteins: chronology and critique. In: Neurotoxicology, Tilson H, Mitchell C (eds) pp. 83-100. New York: Raven Press, 1992.
91. Whitaker JN, Snyder DS. Myelin components in the cerebrospinal fluid in diseases affecting central nervous system myelin. Clin Immunol Allerg 1982; 2: 469-482.
92. Mastroianni CA et al. Detection of cerebrospinal fluid antibodies against myelin basic protein in patients with AIDS dementia comples. Mol Chem Neuropathol 1991; 14: 227-235.
93. Singh VK et al. Antibodies to myelin basic protein in children with autistic behaviour. Brain Behav Immunol 1993; 7: 97-103.
94. Waterman SJ, El-Fawai HAN, Snyder CA. Lead alters the immunogenicity of two neural proteins: a potential mechanism for the progression of lead-induced neurotoxicity. Environ Health Persp 1994; 102: 1052-1056.
95. El-Gazzar RM, Shamy MY, Moneim AI, El-Fawal H. Occupational exposure to mercury results in serum autoantibodies to neurotypic and gliotypic protein. Toxicologist 1994; 14: 291.
96. Moneim AI, Shamy MY, El-Gazzar RM, El-Fawal H. Autoantibodies to neurofilaments (NF), glial fibrillary acid protein (GFAP), and myelin basic proteins (MBP) in workers exposed to lead. Toxicologist 1994; 14: 291.
97. Payne T, Newmark J, Reid KH. The focally demyelinated rat fimbria: a new in vitro model for the study of acute demyelination in the central nervous system. Neurology 1991; 114: 66-72.
98. Liu X, Ray DE. Cerebellar surface auditory evoked potential: the effect of intracerebellar procaine in anaesthetised rats. J Physiol 1995; 483: 29P.
99. Veronesi B, Jones K, Pringle J, Mezei C. Myelin basic protein messenger RNA expression during triethyltin-induced myelin edema. Neurotoxicology 1991; 12: 215-276.
100. Paschen W. Polyamine metabolism in different pathological states of the brain. Mol Chem Neuropathol 1992; 16: 241-271.
101. Hessels J, Ferwerda H, Kingma AW, Muskiet AJ. Inhibition of polyamine oxidase in rats improves the sensitivity of urinary polyamines as markers of cells death. Biochem J 1990; 266: 843-851.
102. Ali SF, Newport GD, Slikker W, Bondy SC. Effect of trimethyltin on ornithine decarboxylase in various regions of the mouse brain. Toxicology Letters 1987; 36: 67-72.
103. Martinez E, de Vera N, Artigas F. Differential response of rat brain polyamines to convulsant agents. Life Sciences 1991; 48: 77-84.
104. de Vera N, Serratosa J, Artigas F, Martinez E. Toxic effects of putrescine in rat brain: Polyamines can be involved in the action of excitotoxins. Amino Acids 1992; 3: 261-269.
105. Camón L, de Vera N, Martinez E. On the neurotoxicity of systemically administered putrescine: influence of kinetic factors. Neurotoxicology 1994; 15: 759-764.
106. de Vera N, Camón L, Martínez E. Blood polyamines after status epilepticus elicited by kainic acid in the rat. Biogenic Amines, 1995; 11: 165-176.
107. Soderkvist P, Axelson O. On the use of molecular biology data in occupational and environmental medicine. JOEM; 37: 85-90.
108. Martin PR, McCool BA, Singleton CK. Genetic sensitivity to thiamine deficiency and development of alcoholic organic brain disease. Alcohol Clin Exp Res 1993; 17: 31-37.
109. Wetmur JG, Kaya AH, Plewinska M, Desnick RJ. Molecular characterization of the human delta-aminolevulinate dehydratase 2 [ALAD2) allele: implications for molecular screening of individuals for genetic susceptibility to lead. Am J Hum Genetics 1991; 49: 757-763.
110. Smith CM, Wang X, Hu H, Kelsey KT. A polymorphism in the delta-aminolevulinic acid dehydratase gene may modify the pharmacokinetics and toxicity of lead. Environ Health Pers 1995; 103: 248-253.
111. Humbert R et al. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet 1993; 3: 73-76.
112. Li WF, Costa LG, Furlong CE. Serum paraoxonase status: a major factor in determining resistance to organophosphates. J Toxicol Environ Health 1993; 40: 337-346.
113. Da Prada M, Cesura AM, Launay JM, Richards JG. The platelet in pathophysiological research. Platelets is a model for neurones? Experientia 1988, 44: 115-127.
114. Reichlin S. Neuroendocrine-immune interactions. N Engl J Med 1993; 329: 1246-1253.
115. Blass JP, Gibson GE. Noneural markers in Alzheimer disease. Alz Dis Assoc Dis 1993; 6: 205-224.
116. Burger D, Steck AJ. Neuropathies associated with antimyelin antibodies. In: Immunology of Neuromuscular Disease. Hohlfeld L (ed) pp. 7-31. Dordrecht: Kluver, 1994.
117. Javaid JI et al. Peripheral benzodiazepine receptors are decreased during cocaine withdrawal in humans. Biol Psychiat 1994; 36: 44-50.
118. Bergamaschi E et al. Peripheral markers of neurochemical effects among styrene-exposed workers. Neurotoxicology, in press.